Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia

Leuk Lymphoma. 2024 May;65(5):684-687. doi: 10.1080/10428194.2024.2304026. Epub 2024 Jan 22.

Authors

Tamar Tadmor^{1

2}, Ilana Levy Yurkovski^{1

2}

Affiliations

¹ Hematology Unit, Bnai Zion Medical Center, Haifa, Israel.
² Rappaport Faculty of Medicine, Technion International Institute of Technology, Haifa, Israel.

PMID: 38247446
DOI: 10.1080/10428194.2024.2304026

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Bispecific* / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use
Drug Resistance, Neoplasm
Female
Humans
Leukemia, Hairy Cell* / drug therapy
Middle Aged
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / pathology
Recurrence
Treatment Outcome

Substances

Antibodies, Bispecific
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological